LSL Pharma Group Statistics

Total Valuation

LSL Pharma Group has a market cap or net worth of CAD 38.70 million. The enterprise value is 52.58 million.

Market Cap	38.70M
Enterprise Value	52.58M

Important Dates

The next estimated earnings date is Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	n/a

Share Statistics

LSL Pharma Group has 115.53 million shares outstanding. The number of shares has increased by 24.72% in one year.

Current Share Class	n/a
Shares Outstanding	115.53M
Shares Change (YoY)	+24.72%
Shares Change (QoQ)	+8.86%
Owned by Insiders (%)	23.88%
Owned by Institutions (%)	n/a
Float	79.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.05
PB Ratio	1.90
P/TBV Ratio	3.45
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 80.65, with an EV/FCF ratio of -10.77.

EV / Earnings	-21.44
EV / Sales	3.32
EV / EBITDA	80.65
EV / EBIT	n/a
EV / FCF	-10.77

Financial Position

The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.69.

Current Ratio	1.17
Quick Ratio	0.42
Debt / Equity	0.69
Debt / EBITDA	21.54
Debt / FCF	-2.88
Interest Coverage	-0.34

Financial Efficiency

Return on equity (ROE) is -16.28% and return on invested capital (ROIC) is -1.35%.

Return on Equity (ROE)	-16.28%
Return on Assets (ROA)	-1.16%
Return on Capital (ROIC)	-1.35%
Revenue Per Employee	138,789
Profits Per Employee	-21,509
Employee Count	114
Asset Turnover	0.47
Inventory Turnover	2.50

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.91% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-23.91%
50-Day Moving Average	0.42
200-Day Moving Average	0.45
Relative Strength Index (RSI)	35.91
Average Volume (20 Days)	33,325

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, LSL Pharma Group had revenue of CAD 15.82 million and -2.45 million in losses. Loss per share was -0.03.

Revenue	15.82M
Gross Profit	3.98M
Operating Income	-626,000
Pretax Income	-2.45M
Net Income	-2.45M
EBITDA	427,000
EBIT	-626,000
Loss Per Share	-0.03

Full Income Statement

Balance Sheet

The company has 164,000 in cash and 14.04 million in debt, giving a net cash position of -13.88 million or -0.12 per share.

Cash & Cash Equivalents	164,000
Total Debt	14.04M
Net Cash	-13.88M
Net Cash Per Share	-0.12
Equity (Book Value)	20.37M
Book Value Per Share	0.18
Working Capital	1.41M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.09 million and capital expenditures -2.79 million, giving a free cash flow of -4.88 million.

Operating Cash Flow	-2.09M
Capital Expenditures	-2.79M
Free Cash Flow	-4.88M
FCF Per Share	-0.04

Full Cash Flow Statement

Margins

Gross margin is 25.13%, with operating and profit margins of -3.96% and -15.50%.

Gross Margin	25.13%
Operating Margin	-3.96%
Pretax Margin	-15.50%
Profit Margin	-15.50%
EBITDA Margin	2.70%
EBIT Margin	-3.96%
FCF Margin	n/a

Dividends & Yields

LSL Pharma Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.72%
Shareholder Yield	-24.72%
Earnings Yield	-7.55%
FCF Yield	-12.61%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LSL Pharma Group has an Altman Z-Score of 1.2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.2
Piotroski F-Score	n/a